David Dalgarno - Oct 6, 2021 Form 3 Insider Report for Theseus Pharmaceuticals, Inc. (THRX)

Role: Chief Technical Officer
Signature: /s/ Bradford Dahms - Attorney-in-Fact
Stock symbol: THRX
Transactions as of: Oct 6, 2021
Transactions value $: $0
Form type: 3
Date filed: 10/6/2021, 07:00 PM
Next filing: Feb 23, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	THRX	Common Stock						388K	Oct 6, 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	THRX	Stock Option (right to buy)							Oct 6, 2021	Common Stock	344K	$0.32	Direct	F1
holding	THRX	Stock Option (right to buy)							Oct 6, 2021	Common Stock	36.1K	$4.03	Direct	F2
holding	THRX	Stock Option (right to buy)							Oct 6, 2021	Common Stock	61.5K	$4.03	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The options are immediately exercisable in full due to early exercise rights, subject to the issuer's right of repurchase. The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 1/48th of the options vesting monthly after November 18, 2020, subject to the Reporting Person's continuous service with the issuer
F2	The options are immediately exercisable in full due to early exercise rights, subject to the issuer's right of repurchase. The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 1/48th of the options vesting monthly after November 18, 2020, subject to the Reporting Person's continuous service with the issuer.
F3	The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 1/48th of the options vesting monthly after May 27, 2021, subject to the Reporting Person's continuous service with the issuer.